Study protocol for a randomised, double-blind, placebo-controlled study evaluating the Efficacy of cannabis-based Medicine Extract in slowing the disease pRogression of Amyotrophic Lateral sclerosis or motor neurone Disease: the EMERALD trial
Authors:
Open Access
Abstract
Introduction Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disorder with no known cure and with an average life expectancy of 3–5 years post diagnosis. The use of complementary medicine such as medicinal cannabis in search for a potential treatment or cure is common in ALS. Preclinical studies have demonstrated the efficacy of cannabinoids in extending the survival and slowing of disease progression in animal models with ALS. There are anecdotal reports of cannabis slowing disease progression in persons with ALS (pALS) and that cannabis alleviated the symptoms of spasticity and pain. However, a clinical trial in pALS with these objectives has not been conducted. Methods and analysis The Efficacy of cannabis-based Medicine Extract in slowing the disease pRogression of Amyotrophic Lateral sclerosis or motor neurone Disease trial is a randomised, double-blind, placebo-controlled cannabis trial in pALS conducted at the Gold Coast University Hospital, Australia. The investigational product will be a cannabis-based medicine extract (CBME) supplied by CannTrust Inc., Canada, with a high-cannabidiol-low-tetrahydrocannabinol concentration. A total of 30 pALS with probable or definite ALS diagnosis based on the El Escorial criteria, with a symptom duration of Ethics and dissemination The study has been approved by the local Institutional Review Board. The results of this study will be published in a peer-reviewed journal. Trial registration number NCT03690791Keywords
Funding Information
- Gold Coast Hospital and Health Service and Gold Coast Hospital Foundation Research Grants Scheme (LG0003)
This publication has 38 references indexed in Scilit:
- Safety and efficacy of nabiximols on spasticity symptoms in patients with motor neuron disease (CANALS): a multicentre, double-blind, randomised, placebo-controlled, phase 2 trialThe Lancet Neurology, 2019
- Practical considerations in medical cannabis administration and dosingEuropean Journal of Internal Medicine, 2018
- Amyotrophic Lateral SclerosisNew England Journal of Medicine, 2017
- Current Therapeutic Cannabis Controversies and Clinical Trial Design IssuesFrontiers in Pharmacology, 2016
- Changes in Endocannabinoid Receptors and Enzymes in the Spinal Cord of SOD1G93A Transgenic Mice and Evaluation of a Sativex®‐like Combination of Phytocannabinoids: Interest for Future Therapies in Amyotrophic Lateral SclerosisCNS Neuroscience & Therapeutics, 2014
- Cannabidiol in Humans—The Quest for Therapeutic TargetsPharmaceuticals, 2012
- ALSUntangled No. 16: CannabisAmyotrophic Lateral Sclerosis, 2012
- The CB2 cannabinoid agonist AM‐1241 prolongs survival in a transgenic mouse model of amyotrophic lateral sclerosis when initiated at symptom onsetJournal of Neurochemistry, 2007
- Increasing cannabinoid levels by pharmacological and genetic manipulation delays disease progression in SOD1 miceThe FASEB Journal, 2006
- Cannabinoids and neuroinflammationBritish Journal of Pharmacology, 2004